참고문헌 (67)

1. Immunity Anderson 44 989 2016 10.1016/j.immuni.2016.05.001 Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation 

   상세보기

2. Cancers Ando 12 2020 Nivolumab plus ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis 

   상세보기

3. BioRxiv Banerjee 2020 Expression of Tim-3 drives naïve Treg to an effector-like state with enhanced suppressive activity 

4. Cell Mol. Immunol. Bhattacharyya 7 306 2010 10.1038/cmi.2010.11 Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts 

   상세보기

5. Nature reviews Boutros 13 473 2016 Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination 

6. Immunotherapy. Front Cell Dev. Biol. Canning 7 52 2019 10.3389/fcell.2019.00052 Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on 

   상세보기

7. Oral oncol. Chang 52 66 2016 10.1016/j.oraloncology.2015.11.002 EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity 

   상세보기

8. CA-Cancer J. Clin. Chi 65 401 2015 10.3322/caac.21293 Oral cavity and oropharyngeal squamous cell carcinoma-an update 

   상세보기

9. Int. J. Mol. Sci. Chou 19 430 2018 10.3390/ijms19020430 Role of galectins in tumors and in clinical immunotherapy 

   상세보기

10. J. Clin. Oncol. Chow 34 3838 2016 10.1200/JCO.2016.68.1478 Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort 

    상세보기

11. Cancer Cognetti 113 1911 2008 10.1002/cncr.23654 Head and neck cancer: an evolving treatment paradigm 

    상세보기

12. Cancer Prev. Res. (Philadelphia, Pa.) Czerninski 2 27 2009 10.1158/1940-6207.CAPR-08-0147 Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model 

    상세보기

13. Oncoimmunology de Ruiter 6 2017 10.1080/2162402X.2017.1356148 The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis 

    상세보기

14. Oral Dis. Deng 24 120 2018 10.1111/odi.12746 Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma 

    상세보기

15. The Yale J. Biol. Med. Dimberu 84 371 2011 Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear 

    상세보기

16. Front Oncol. Dong 8 386 2018 10.3389/fonc.2018.00386 Tumor-Intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion 

    상세보기

17. Int. J. Cancer Ferlay 136 E359 2015 10.1002/ijc.29210 Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 

    상세보기

18. The New Engl. J. Med. Ferris 375 1856 2016 10.1056/NEJMoa1602252 Nivolumab for recurrent squamous-cell carcinoma of the head and neck 

    상세보기

19. PloS one Gao 7 e30676 2012 10.1371/journal.pone.0030676 TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression 

    상세보기

20. Eur. J. Immunol. Gautron 44 2703 2014 10.1002/eji.201344392 Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells 

    상세보기

21. PloS one Geißler 12 2017 10.1371/journal.pone.0183214 Functional characterization of T-cells from palatine tonsils in patients with chronic tonsillitis 

    상세보기

22. Oral oncol. Ghanizada 90 67 2019 10.1016/j.oraloncology.2019.01.018 The effects of checkpoint inhibition on head and neck squamous cell carcinoma: a systematic review 

    상세보기

23. Onco. Targets Ther. Guo 11 7635 2018 10.2147/OTT.S177329 Clinicopathological analysis of PD-L2 expression in colorectal cancer 

    상세보기

24. Front Genet. Hassan 10 514 2019 10.3389/fgene.2019.00514 Curcumin as an alternative epigenetic modulator: mechanism of action and potential effects 

    상세보기

25. Cancer Sci. Hayakawa 111 4326 2020 10.1111/cas.14675 Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3 

    상세보기

26. Clin. Drug. Invest. Ji 39 319 2019 10.1007/s40261-018-0735-0 Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS 

    상세보기

27. Cancer Lett. Jiang 468 72 2020 10.1016/j.canlet.2019.10.013 Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion 

    상세보기

28. Cancer Immunol. Res. Jie 5 408 2017 10.1158/2326-6066.CIR-16-0333 Increased PD-1(+) and TIM-3(+) TILs during Cetuximab therapy inversely correlate with response in head and neck cancer patients 

    상세보기

29. Clin. Exp. Otorhinolar Joo 12 107 2019 10.21053/ceo.2018.01816 Guidelines for the surgical management of oral cancer: korean society of thyroid-head and neck surgery 

    상세보기

30. J. Oncol. 2019 Joshi 2019 Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system 

31. Oral oncol. Kanojia 42 655 2006 10.1016/j.oraloncology.2005.10.013 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis 

    상세보기

32. Nat. Med. Khuri 6 879 2000 10.1038/78638 a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer 

    상세보기

33. Clin. Exp. Otorhinolar Kim 13 69 2020 10.21053/ceo.2019.00388 Evaluation of prognostic factors for the parotid cancer treated with surgery and postoperative radiotherapy 

    상세보기

34. Nat. Commun. Koyama 7 10501 2016 10.1038/ncomms10501 Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints 

    상세보기

35. Indian J. Pharm Sci. Kulkarni 72 149 2010 10.4103/0250-474X.65012 An overview of curcumin in neurological disorders 

    상세보기

36. Cancer Growth Metastasis Landis-Piwowar 7 19 2014 10.4137/CGM.S11288 Cancer chemoprevention: current state of the art 

    상세보기

37. Cancer Treat. Rev. Laskin 30 1 2004 10.1016/j.ctrv.2003.10.002 Epidermal growth factor receptor: a promising target in solid tumours 

    상세보기

38. Tumour Biol. Li 39 2017 TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas 

    상세보기

39. Arch. Oral Biol. Liao 92 32 2018 10.1016/j.archoralbio.2018.04.015 Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma 

    상세보기

40. Cancer cell Lim 30 925 2016 10.1016/j.ccell.2016.10.010 Deubiquitination and stabilization of PD-L1 by CSN5 

    상세보기

41. BMC cancer Mansouri 20 791 2020 10.1186/s12885-020-07256-8 Clinical effects of curcumin in enhancing cancer therapy: a systematic review 

    상세보기

42. Clin. Exp. Immunol. Martinelli 158 1 2009 10.1111/j.1365-2249.2009.03992.x Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy 

    상세보기

43. Int. J. Oral Sci. Mei 12 16 2020 10.1038/s41368-020-0084-8 Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma 

    상세보기

44. Eur. Urol. Niglio 76 782 2019 10.1016/j.eururo.2019.05.037 Programmed death-1 or programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: a systematic review and meta-analysis 

    상세보기

45. Front Oncol. Park 10 258 2020 10.3389/fonc.2020.00258 Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-Analysis 

    상세보기

46. Hematol. Oncol. Clin. North Am. Puram 29 971 2015 10.1016/j.hoc.2015.07.003 Molecular aspects of head and neck cancer therapy 

    상세보기

47. Curr. Med. Chem. Rahimi 2020 Curcumin: a dietary phytochemical for targeting the phenotype and function of dendritic cells 

48. Cell Death Dis. Ren 10 261 2019 10.1038/s41419-019-1497-1 Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways 

    상세보기

49. J. Exp. Med. Sakuishi 207 2187 2010 10.1084/jem.20100643 Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity 

    상세보기

50. Oncoimmunology Sakuishi 2 e23849 2013 10.4161/onci.23849 TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer 

    상세보기

51. Lancet Oncol. Seiwert 17 956 2016 10.1016/S1470-2045(16)30066-3 Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial 

    상세보기

52. Pharmacological Res. Shafabakhsh 147 2019 10.1016/j.phrs.2019.104353 Targeting regulatory T cells by curcumin: a potential for cancer immunotherapy 

    상세보기

53. Carcinogenesis Shankar 28 1277 2007 10.1093/carcin/bgm024 Bax and Bak genes are essential for maximum apoptotic response by curcumin, a polyphenolic compound and cancer chemopreventive agent derived from turmeric, Curcuma longa 

    상세보기

54. Oncoimmunology Shayan 6 2017 10.1080/2162402X.2016.1261779 Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer 

    상세보기

55. Inflammation Sun 40 1342 2017 10.1007/s10753-017-0577-6 Tim3(+) Foxp3 (+) Treg cells are potent inhibitors of effector T cells and are suppressed in Rheumatoid arthritis 

    상세보기

56. Asian Pac. J. Cancer Prev. Taghiloo 18 2269 2017 Upregulation of galectin-9 and PD-L1 immune checkpoints molecules in patients with chronic Lymphocytic Leukemia 

    상세보기

57. Clin. Cancer Res. Tang 10 301 2004 10.1158/1078-0432.CCR-0999-3 Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice 

    상세보기

58. CA-Cancer J. Clin. Torre 65 87 2015 10.3322/caac.21262 Global cancer statistics, 2012 

    상세보기

59. Mutat. Res. van Zijl 728 23 2011 10.1016/j.mrrev.2011.05.002 Initial steps of metastasis: cell invasion and endothelial transmigration 

    상세보기

60. Ann. Oncol. Vermorken 21 Suppl 7 vii252 2010 10.1093/annonc/mdq453 Optimal treatment for recurrent/metastatic head and neck cancer 

    상세보기

61. Oral Maxil. Surg. Clin. Vigneswaran 26 123 2014 10.1016/j.coms.2014.01.001 Epidemiologic trends in head and neck cancer and aids in diagnosis 

    상세보기

62. Cancer Med. Weber 8 1124 2019 10.1002/cam4.1929 Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile 

    상세보기

63. Int. J. Cardiol. Wongcharoen 133 145 2009 10.1016/j.ijcard.2009.01.073 The protective role of curcumin in cardiovascular diseases 

    상세보기

64. Nat. Commun. Yao 11 3715 2020 10.1038/s41467-020-17492-y Single-cell transcriptomic analysis in a mouse model deciphers cell transition states in the multistep development of esophageal cancer 

    상세보기

65. Clin. Cancer Res. Yearley 23 3158 2017 10.1158/1078-0432.CCR-16-1761 PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer 

    상세보기

66. Blood Zhou 117 4501 2011 10.1182/blood-2010-10-310425 Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia 

    상세보기

67. Front Physiol. Zhou 9 2018 10.3389/fphys.2018.00452 Galectin-9 expression predicts favorable clinical outcome in solid tumors: a systematic review and meta-analysis 

    상세보기

활용도 Top5 논문

더보기

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.